<DOC>
	<DOCNO>NCT00000794</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerance atovaquone either pyrimethamine sulfadiazine AIDS patient toxoplasmic encephalitis . AIDS patient toxoplasmic encephalitis receive standard therapy combination sulfadiazine pyrimethamine experience high frequency severe toxicity . Atovaquone , antibiotic demonstrate efficacy toxoplasmosis animal model preclinical test well tolerate , available suspension , readily absorb tablet form drug . The efficacy safety atovaquone combination sulfadiazine pyrimethamine study .</brief_summary>
	<brief_title>Phase II Randomized Open-Label Trial Atovaquone Plus Pyrimethamine Atovaquone Plus Sulfadiazine Treatment Acute Toxoplasmic Encephalitis</brief_title>
	<detailed_description>AIDS patient toxoplasmic encephalitis receive standard therapy combination sulfadiazine pyrimethamine experience high frequency severe toxicity . Atovaquone , antibiotic demonstrate efficacy toxoplasmosis animal model preclinical test well tolerate , available suspension , readily absorb tablet form drug . The efficacy safety atovaquone combination sulfadiazine pyrimethamine study . Seventy patient randomize receive atovaquone either pyrimethamine sulfonamides 48 week . Additionally , three cohort 10 patient history treatment-limiting toxicity pyrimethamine , sulfadiazine , drug receive atovaquone plus alternate drug atovaquone plus clarithromycin . All patient receive pyrimethamine also receive leucovorin protection . PER AMENDMENT 4/3/96 : The open treatment group : Atovaquone plus pyrimethamine patient acute toxoplasmic encephalitis treatment limit toxicity pyrimethamine , Atovaquone plus clarithromycin patient acute toxoplasmic encephalitis treatment limit toxicity pyrimethamine sulfadiazine . The following arm close 12/22/95 : Randomization atovaquone plus sulfadiazine arm patient acute toxoplasmic encephalitis treatment limit toxicity pyrimethamine sulfonamide , Atovaquone plus sulfadiazine patient acute toxoplasmic encephalitis treatment limit toxicity pyrimethamine . The following arm close 9/26/95 : Atovaquone plus pyrimethamine patient acute toxoplasmic encephalitis treatment limit toxicity sulfonamide . NOTE : Any patient enrol previous version continue treat drug treatment follow previous version guideline .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Sulfadiazine</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine PCP prophylaxis . PER AMENDMENT 4/3/96 : History treatment limit toxicity pyrimethamine . Patients history treatment limit toxicity pyrimethamine sulfonamide assign receive atovaquone plus clarithromycin . Patients must : Documented HIV infection diagnosis AIDS ( except CD4 count &lt; 200 cells/mm3 ) . Toxoplasmic encephalitis . Ability give inform consent legal designee could give consent . PER AMENDMENT 4/3/96 : NOTE A history treatment limit toxicity pyrimethamine sulfonamide result patient enrol atovaquone plus clarithromycin arm . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Coma . Opportunistic infection require either acute maintenance treatment disallow medication . Any infection neoplasms central nervous system Toxoplasma , HIV encephalopathy , syphilis . Unable take oral study drug . Malabsorption ( i.e. , three episode diarrhea per day cause &gt; = 10 percent loss body weight past 4 week ) . Positive CSF serum Cryptococcus antigen culture ( positive serum antigen acceptable , provided patient receive prior antifungal therapy maintenance , likelihood recurrence low ) . Malignancy require use cytotoxic chemotherapy . Medical social condition would adversely affect study participation compliance . Concurrent Medication : Excluded : Trimethoprimsulfamethoxazole . Primaquine . Sulfonamides . Antifolates . Dapsone . Clarithromycin ( except patient cohort receive drug ) . Azithromycin . Clindamycin . Other macrolides . Gamma interferon . Metoclopramide . GCSF GMCSF . Excluded patient receive clarithromycin study drug : Terfenadine , astemizole , longacting , nonsedating antihistamine . PER AMENDMENT 4/3/96 : Cisapride may increase GI motility may increase drug absorption . Patients follow prior condition exclude : History treatmentlimiting toxicity atovaquone . Receipt &gt; 96 hour ( per amendment ) treatment prior study entry current episode toxoplasmic encephalitis .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pyrimethamine</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>atovaquone</keyword>
	<keyword>Toxoplasmosis , Cerebral</keyword>
	<keyword>Sulfadiazine</keyword>
</DOC>